• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

    31.64 +0.23 (+0.72%)
    Streaming Delayed Price Updated: 11:21 AM EST, Jan 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Teva Pharmaceutical Industries Limited American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    News headline image
    AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
    Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) 
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
    According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain... 
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Releases Q4 2025 Aide Memoire
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Releases Q3 2025 Aide Memoire
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Releases Q2 2025 Aide Memoire
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.